Teachers Retirement System of The State of Kentucky lessened its position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Get Rating) by 6.7% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 8,400 shares of the medical device company's stock after selling 600 shares during the quarter. Teachers Retirement System of The State of Kentucky's holdings in Tandem Diabetes Care were worth $977,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. BlackRock Inc. increased its stake in Tandem Diabetes Care by 0.8% in the 1st quarter. BlackRock Inc. now owns 6,531,074 shares of the medical device company's stock worth $759,496,000 after buying an additional 52,436 shares during the period. Vanguard Group Inc. increased its stake in Tandem Diabetes Care by 2.4% in the 1st quarter. Vanguard Group Inc. now owns 6,306,724 shares of the medical device company's stock worth $733,408,000 after buying an additional 146,577 shares during the period. Capital World Investors increased its stake in Tandem Diabetes Care by 4.0% in the 4th quarter. Capital World Investors now owns 3,427,129 shares of the medical device company's stock worth $515,851,000 after buying an additional 133,133 shares during the period. Invesco Ltd. increased its stake in Tandem Diabetes Care by 7.1% in the 1st quarter. Invesco Ltd. now owns 2,080,173 shares of the medical device company's stock worth $241,904,000 after buying an additional 137,202 shares during the period. Finally, State Street Corp increased its stake in Tandem Diabetes Care by 3.6% in the 1st quarter. State Street Corp now owns 1,708,030 shares of the medical device company's stock worth $198,627,000 after buying an additional 59,778 shares during the period. Institutional investors own 95.28% of the company's stock.

Analyst Ratings Changes

Several research analysts recently commented on the stock. TheStreet downgraded shares of Tandem Diabetes Care from a "c-" rating to a "d+" rating in a research note on Monday, June 13th. Wells Fargo & Company downgraded shares of Tandem Diabetes Care from an "overweight" rating to an "underweight" rating and cut their target price for the company from $82.00 to $49.00 in a research report on Tuesday, August 9th. Cowen cut their target price on shares of Tandem Diabetes Care from $141.00 to $107.00 in a research report on Thursday, August 4th. Piper Sandler cut their target price on shares of Tandem Diabetes Care from $120.00 to $80.00 and set an "overweight" rating on the stock in a research report on Thursday, August 4th. Finally, StockNews.com raised shares of Tandem Diabetes Care from a "sell" rating to a "hold" rating in a research report on Friday. One analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $103.36.

Tandem Diabetes Care Stock Up 0.2 %

About Tandem Diabetes Care

(Get Rating)

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.

Further Reading

• Get a free copy of the StockNews.com research report on Tandem Diabetes Care (TNDM)
• MarketBeat: Week in Review 9/19 – 9/23
• Why Does Tesla Stock Remain Resilient?
• Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
• 2 Semiconductor Stocks To Watch For Reversals
• Is Costco's Post-Earnings Price Weakness A Good Time To Buy?

Want to see what other hedge funds are holding TNDM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Get Rating).

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.